MarketResearchNest.com adds “Acromegaly – Pipeline Review, H2 2017” new report to its research database. The report spread across 80 pages with table and figures in it.
Acromegaly – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly – Pipeline Review, H2 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.
Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.
Browse full table of contents and data tables at
The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 4, 1, 6 and 3 respectively.
Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Ltd, Chiasma Inc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dauntless Pharmaceuticals Inc, DexTech Medical AB, Foresee Pharmaceuticals LLC, Glide Pharmaceutical Technologies Ltd, Ionis Pharmaceuticals Inc, Ipsen SA, Italfarmaco SpA, Midatech Pharma Plc, Novartis AG, Peptron Inc, Silence Therapeutics Plc,
Strongbridge Biopharma plc, Sun Pharma Advanced Research Company Ltd.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262567
Featured News & Press Releases
Sep 04, 2017: Midatech Submits MTD201 CTA Filing For First-in Human Study in Carcinoid Cancer And Acromegaly
Aug 10, 2017: Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
May 04, 2017: Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
Jul 13, 2016: ATL1103 Patent Update
Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Acromegaly on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain